The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / No Evidence to Support Biologic Switching Guidelines for JIA

No Evidence to Support Biologic Switching Guidelines for JIA

April 1, 2020 • By Marilynn Larkin

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—For young people with juvenile idiopathic arthritis (JIA) who don’t achieve disease control, switching to a different class of biologic is unlikely to be beneficial, researchers say.

You Might Also Like
  • Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
  • Adalimumab + Methotrexate Effective for Uveitis in JIA

The observational study yielded no evidence to support or refute the 2015 National Health Service England guidelines, which recommend switching most patients to a second TNF inhibitor, or the 2019 guidelines of the ACR, which recommend switching patients to an alternative class of biologic (e.g., tocilizumab or abatacept).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“There are differing opinions on which biologic drugs [these children] should receive, and in which order, should they not respond to or be intolerant of methotrexate and a first biologic, often an anti-TNF,” Dr. Kimme Hyrich of the University of Manchester, UK, tells Reuters Health by email. “Our study found after a first biologic, usually a TNF inhibitor, similar outcomes were seen after one year between children who started a second anti-TNF or an alternative class, primarily the IL-6 inhibitor tocilizumab.”

Due to the study’s small size, she notes, “it was not possible to study further whether there are certain children who may still benefit more than others from switching class.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“This emphasizes the need to continue to recruit children into clinical studies so that a large evidence base can be generated to better inform practice for this relatively uncommon disease,” she adds.

As reported in The Lancet Rheumatology, Dr. Hyrich and colleagues analyzed 2,361 young people enrolled upon initiation of biologic therapy in two parallel UK cohort studies between 2004 and 2019.1

From 2010 onwards, 1,152 patients started their first biologic, mostly (91%) with TNF inhibitors. The median follow-up was 2.2 years, during which time, 270 (23%) started a second biologic; 61 (5%) started a third biologic; and 11 (1%) started a fourth.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

In a subgroup of 240 patients with polyarticular course juvenile idiopathic arthritis, 194 (81%) started a second TNF inhibitor and 46 (19%) started a different class of biologic after an initial TNF inhibitor failed.

The choice of second therapy – i.e., second TNF inhibitor or another class of biologic—did not affect the proportion of patients who achieved an ACR Pediatric (ACR Pedi) 90 response (adjusted odds ratio, 2.5) or minimal disease activity (aOR, 1.6).

The authors note that the study did not capture data on treatment adherence, drug levels, or anti-drug antibody concentrations, which might have influenced treatment response – nor was the route or frequency of biologic administration investigated, which might have influenced treatment choice.

Pages: 1 2 | Single Page

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: Biologics, JIA, juvenile idiopathic arthritis (JIA), Pediatric

You Might Also Like:
  • Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA
  • Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
  • Adalimumab + Methotrexate Effective for Uveitis in JIA
  • New Guidance for Rheumatologists who Treat JIA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.